Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have been assigned an average rating of "Hold" from the nine ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $8.63.

Separately, HC Wainwright restated a "neutral" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th.

Fulcrum Therapeutics Stock Performance

NASDAQ FULC traded down $0.13 during trading hours on Friday, hitting $3.46. The company had a trading volume of 48,268 shares, compared to its average volume of 938,437. The business has a 50 day moving average of $3.15 and a 200-day moving average of $3.61. The company has a market cap of $186.77 million, a PE ratio of -11.15 and a beta of 2.13. Fulcrum Therapeutics has a 1-year low of $2.32 and a 1-year high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). Sell-side analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors have recently bought and sold shares of FULC. Mackenzie Financial Corp lifted its stake in shares of Fulcrum Therapeutics by 412.5% during the fourth quarter. Mackenzie Financial Corp now owns 118,025 shares of the company's stock worth $555,000 after purchasing an additional 94,997 shares in the last quarter. Woodline Partners LP grew its holdings in Fulcrum Therapeutics by 110.3% during the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock valued at $6,629,000 after purchasing an additional 739,713 shares in the last quarter. Suvretta Capital Management LLC increased its stake in Fulcrum Therapeutics by 182.3% during the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock worth $15,691,000 after buying an additional 2,155,675 shares during the period. Shay Capital LLC boosted its holdings in Fulcrum Therapeutics by 4.2% in the fourth quarter. Shay Capital LLC now owns 301,464 shares of the company's stock valued at $1,417,000 after purchasing an additional 12,227 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of Fulcrum Therapeutics by 224.0% in the fourth quarter. Millennium Management LLC now owns 76,123 shares of the company's stock worth $358,000 after buying an additional 52,628 shares during the last quarter. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.